Plasma microRNA test boosts lung cancer screening
The ability to screen for lung cancer is improved by the development of a plasma 24-microRNA signature classifier, research suggests. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 28, 2014 Category: Cancer & Oncology Source Type: news

H4 receptor activation plays part in NSCLC progression
Histamine H4 receptor activation decreases epithelial-to-mesenchymal transmission in non-small-cell lung cancer, Chinese research shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 27, 2014 Category: Cancer & Oncology Source Type: news

Novel SCLC tumour suppressor gene discovered
Inactivation of the MYC-associated factor X gene, MAX, may play a significant role in the development of small-cell lung cancer, scientists believe. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 26, 2014 Category: Cancer & Oncology Source Type: news

Perioperative blood transfusion worsens kidney cancer patients’ survival
Patients who receive blood transfusions around the time of their surgery for nonmetastatic renal cell carcinoma have a worse chance of survival than those who do not, results of a large US study suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 24, 2014 Category: Cancer & Oncology Source Type: news

Sedentary behaviour has unclear link with prostate cancer risk
Sedentary behaviour is not a clearcut risk factor for prostate cancer, analysis of a large population-based cohort indicates. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 24, 2014 Category: Cancer & Oncology Source Type: news

Partial nephrectomy may offer younger renal cancer patients survival advantage
Partial nephrectomy may offer younger patients with localized renal cancer a distinct survival advantage compared with the complete removal of the kidney, US research suggests. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 24, 2014 Category: Cancer & Oncology Source Type: news

Advanced age should not preclude sunitinib use for mRCC
Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 21, 2014 Category: Cancer & Oncology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 21, 2014 Category: Cancer & Oncology Source Type: news

EGFR–TKI tumour response predicts NSCLC survival
A partial or complete response to epidermal growth factor receptor tyrosine kinase inhibitor therapy is significantly associated with survival in patients with non-small-cell lung cancer, research suggests. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 20, 2014 Category: Cancer & Oncology Source Type: news

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC
Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 19, 2014 Category: Cancer & Oncology Source Type: news

Afatinib ‘first line’ for advanced mutation-positive lung cancer
Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 17, 2014 Category: Cancer & Oncology Source Type: news

Splicing findings offer lung cancer clues
Researchers from Spain have identified several new splicing events regulated by the oncogenic splicing factor SRSF1 in lung cancer, suggesting that their dysregulation is involved in the pathogenesis of the disease. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 4, 2014 Category: Cancer & Oncology Source Type: news

Primary tumor, node location important in stage III NSCLC prognosis
Researchers from Japan say that classifying clinical mediastinal lymph node status based on the location of the primary tumor and the node involved could improve prognosis in stage III non-small-cell lung cancer compared with pathologic node status. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 3, 2014 Category: Cancer & Oncology Source Type: news

Mesothelin expression prognostic in lung adenocarcinoma
Mesothelin expression is a significant predictor for tumor aggression in patients with lung adenocarcinoma, suggest study findings published in Clinical Cancer Research. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 31, 2014 Category: Cancer & Oncology Source Type: news

RNAi-based screening offers MPM treatment hope
Research using RNA interference-based screening has identified several potential targets for the treatment of malignant pleural mesothelioma. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 31, 2014 Category: Cancer & Oncology Source Type: news

Everolimus fails to boost advanced NSCLC response
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 28, 2014 Category: Cancer & Oncology Source Type: news

South Korean lung SCC genetic secrets revealed
Close examination of DNA taken from squamous cell carcinoma of the lung in South Korean patients has identified a gene fusion that may be targeted by current treatments, scientists say. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 27, 2014 Category: Cancer & Oncology Source Type: news

Sling technique boosts post-RARP early continence recovery
Researchers have shown that addition of the bladder neck sling suspension technique to robot-assisted radical prostatectomy can improve the early return of continence after surgery. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 27, 2014 Category: Cancer & Oncology Source Type: news

Novel HER2 mutation identified in familial lung adenocarcinomas
Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 24, 2014 Category: Cancer & Oncology Source Type: news

Immunotherapy maintenance shows promise in NSCLC
Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 24, 2014 Category: Cancer & Oncology Source Type: news

Etoposide plus cisplatin remains best for limited-stage SCLC
Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 23, 2014 Category: Cancer & Oncology Source Type: news

Overdiagnosis concerns raised for CT lung cancer screening
People participating in any future computed tomography lung cancer screening program would face a significant risk for overdiagnosis, US researchers caution in JAMA Internal Medicine. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 22, 2014 Category: Cancer & Oncology Source Type: news

Nomogram predicts overdiagnosis in prostate cancer screening
US researchers have developed a nomogram which they say can be used to predict whether prostate cancer has been overdiagnosed in individual patients diagnosed following prostate-specific antigen screening. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 20, 2014 Category: Cancer & Oncology Source Type: news

Call for long follow-up after CIN3 treatment
Researchers from Sweden say that women who have been treated for cervical precancer should receive lifelong follow-up, after finding that their risk for dying from vaginal or cervical cancer markedly increases after the age of 60 years. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 15, 2014 Category: Cancer & Oncology Source Type: news

Perioperative analgesia may improve prostate cancer outcomes
Neuraxial analgesia added to general anesthesia for radical retropubic prostatectomy may lead to improved oncologic outcomes in prostate cancer, US researchers have found. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 11, 2014 Category: Cancer & Oncology Source Type: news

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 17, 2013 Category: Cancer & Oncology Source Type: news

Selenium fails to protect NSCLC patients against second primary tumors
Selenium supplementation does not reduce the risk for second primary tumors in patients with resected non–small-cell lung cancer, researchers say. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 17, 2013 Category: Cancer & Oncology Source Type: news

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 16, 2013 Category: Cancer & Oncology Source Type: news

Chest wall resection effective for recurrent mesothelioma
Salvage chest wall resection could lengthen survival in patients with isolated chest wall recurrence of malignant pleural mesothelioma, research indicates. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 16, 2013 Category: Cancer & Oncology Source Type: news

Cetuximab fails in second-line combination for recurrent NSCLC
Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 13, 2013 Category: Cancer & Oncology Source Type: news

Pemetrexed, paclitaxel regimens equally effective in NSCLC
PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 10, 2013 Category: Cancer & Oncology Source Type: news

Low sodium levels linked to poor targeted therapy outcomes in RCC
Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news

Early tumor shrinkage predicts targeted therapy efficacy in RCC
Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news

Novel multi-kinase inhibitor shows early promise in NSCLC
Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news

Training advised to plug lung cancer care gaps
Guideline-consistent care for patients with suspected lung cancer with mediastinal lymphadenopathy without distant metastases varies by region and physician characteristics, say researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 5, 2013 Category: Cancer & Oncology Source Type: news

Lung cancer is costliest cancer in European Union
The total cost of cancer care across the European Union was an estimated € 126 billion in 2009, with lung cancer having the highest cost, at 15% of the total. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 4, 2013 Category: Cancer & Oncology Source Type: news

Investigational c-Met inhibitor shows early promise in NSCLC
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 3, 2013 Category: Cancer & Oncology Source Type: news

Clinicians ‘nihilistic’ toward lung cancer patients
Clinicians tend to view their lung cancer patients more negatively than patients with other solid tumors, study findings indicate. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 3, 2013 Category: Cancer & Oncology Source Type: news

Four-drug regimen shows first-line efficacy in advanced NSCLC
A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 2, 2013 Category: Cancer & Oncology Source Type: news

Endobronchial ultrasound has edge for lung cancer staging
Endobronchial ultrasound-guided transbronchial needle aspiration is a better primary procedure than endoscopic ultrasound-guided fine needle aspiration for staging non-small-cell lung cancer, study results suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 1, 2013 Category: Cancer & Oncology Source Type: news

Smoking reduces nasopharyngeal cancer survival
Both current and former smoking have a significant impact on the prognosis of patients with nasopharyngeal carcinoma, Chinese researchers caution. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 27, 2013 Category: Cancer & Oncology Source Type: news

Medical–surgical integration ‘boosts neoadjuvant chemotherapy use for bladder cancer’
Research from the USA indicates that a multidisciplinary approach and coordination between medical and surgical oncology services can help optimize the use of neoadjuvant chemotherapy for bladder cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 18, 2013 Category: Cancer & Oncology Source Type: news

Pneumococcal pneumonia linked to lung cancer risk
Pneumococcal pneumonia is significantly associated with risk for lung cancer, show findings from a national study in Taiwan. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 13, 2013 Category: Cancer & Oncology Source Type: news

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy
Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 4, 2013 Category: Cancer & Oncology Source Type: news

Current drugs may harbor small-cell lung cancer promise
Scientists have identified several existing non-oncology drug classes that may have potential as a treatment for small-cell lung cancer, especially for patients with chemoresistant and metastatic disease. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 31, 2013 Category: Cancer & Oncology Source Type: news

FDG-PET parameter predicts locally advanced lung cancer survival
High post-treatment concentrations of a radioactive imaging marker are predictive of worse overall survival from inoperable, locally advanced non-small-cell lung cancer, prospective study findings suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 31, 2013 Category: Cancer & Oncology Source Type: news

DNA methylation signature marks recurrence in early stage lung cancer
An international research team has identified a DNA methylation signature that identifies patients with stage I non-small-cell lung cancer who are at high risk for relapse. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 31, 2013 Category: Cancer & Oncology Source Type: news

Complement protein holds diagnostic, prognostic promise in lung cancer
A complement activation product known as “C4d” may have value as a diagnostic and prognostic biomarker for lung cancer, research suggests. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 28, 2013 Category: Cancer & Oncology Source Type: news

REGARD VEGF receptor-2 as gastric cancer target
Targeting vascular endothelial growth factor receptor-2 mediated signaling is an effective strategy against advanced gastric cancer, results from the REGARD trial demonstrate. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 22, 2013 Category: Cancer & Oncology Source Type: news

P400 predicts RCC outcome
Reduced expression of a senescence-associated protein is associated with worse outcome in patients with renal cell carcinoma, study findings show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 22, 2013 Category: Cancer & Oncology Source Type: news